Chao et al., 2014 - Google Patents
Hyperuricemia and the risk of ischemic stroke in patients with atrial fibrillation—could it refine clinical risk stratification in AF?Chao et al., 2014
- Document ID
- 17102427272417755180
- Author
- Chao T
- Liu C
- Chen S
- Wang K
- Lin Y
- Chang S
- Lo L
- Hu Y
- Tuan T
- Chen T
- Tsao H
- Chen S
- Publication year
- Publication venue
- International journal of cardiology
External Links
Snippet
Background Although hyperuricemia has been reported to be a risk factor of stroke, the relationship between hyperuricemia and stroke in patients with atrial fibrillation (AF) remains uncertain. The goal of the present study was to investigate whether hyperuricemia could …
- 201000001431 hyperuricemia 0 title abstract description 80
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/88—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving prostaglandins or their receptors
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
- G06Q50/10—Services
- G06Q50/22—Health care, e.g. hospitals; Social work
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Chao et al. | Hyperuricemia and the risk of ischemic stroke in patients with atrial fibrillation—could it refine clinical risk stratification in AF? | |
El Khoudary et al. | Menopause transition and cardiovascular disease risk: implications for timing of early prevention: a scientific statement from the American Heart Association | |
Guo et al. | Validation of contemporary stroke and bleeding risk stratification scores in non-anticoagulated Chinese patients with atrial fibrillation | |
Fan et al. | Depression after heart failure and risk of cardiovascular and all-cause mortality: a meta-analysis | |
Nyam et al. | Traumatic brain injury increases the risk of major adverse cardiovascular and cerebrovascular events: a 13-year, population-based study | |
Gallagher et al. | Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis? | |
Mehta et al. | Acute myocardial infarction in women: a scientific statement from the American Heart Association | |
Park et al. | Early-and late-term clinical outcome and their predictors in patients with ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction | |
Ruff et al. | Long-term cardiovascular outcomes in patients with atrial fibrillation and atherothrombosis in the REACH Registry | |
Andersson et al. | Gender-related differences in risk of cardiovascular morbidity and all-cause mortality in patients hospitalized with incident atrial fibrillation without concomitant diseases: a nationwide cohort study of 9519 patients | |
Mastenbroek et al. | Disease‐specific health status as a predictor of mortality in patients with heart failure: a systematic literature review and meta‐analysis of prospective cohort studies | |
Reibis et al. | Disparity in risk factor pattern in premature versus late-onset coronary artery disease: a survey of 15,381 patients | |
Kachur et al. | Significance of comorbid psychological stress and depression on outcomes after cardiac rehabilitation | |
Sánchez et al. | Quality of vitamin K antagonist anticoagulation in Spain: prevalence of poor control and associated factors | |
Jover et al. | Predictive value of the CHA2DS2-VASc score in atrial fibrillation patients at high risk for stroke despite oral anticoagulation | |
Gupta et al. | International differences in in-hospital revascularization and outcomes following acute myocardial infarction: a multilevel analysis of patients in ASSENT-2 | |
Ahmed et al. | Differences in symptoms and presentation delay times in myocardial infarction patients with and without diabetes: A cross-sectional study in Pakistan | |
Poli et al. | Epidemiology, diagnosis, and management of atrial fibrillation in women | |
Bazoukis et al. | Impact of major earthquakes on the incidence of acute coronary syndromes–a systematic review of the literature | |
Nauta et al. | Age-dependent care and long-term (20 year) mortality of 14,434 myocardial infarction patients: changes from 1985 to 2008 | |
Seet et al. | Bleeding complications associated with warfarin treatment in ischemic stroke patients with atrial fibrillation: a population-based cohort study | |
Guo et al. | Relation of renal dysfunction to the increased risk of stroke and death in female patients with atrial fibrillation | |
Koivunen et al. | Incidence of sudden cardiac arrest and sudden cardiac death after unstable angina pectoris and myocardial infarction | |
Rodríguez-Mañero et al. | Outcomes of a contemporary sample of patients with atrial fibrillation taking digoxin: results from the AFBAR study | |
Zhang et al. | Relationship of left ventricular thrombus formation and adverse outcomes in acute anterior myocardial infarction in patients treated with primary percutaneous coronary intervention |